Proteomic Applications

  • David H. Geho
  • Lance A. Liotta
  • Emanuel F. Petricoin
Part of the Principles and Practice book series (PRINCIPLES)


Laser Capture Microdissection Proteomic Pattern Color Illustration Proteomic Application Curr Opin Chem Biol 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Adam BL, Vlahou A, Semmes OJ et al. (2001) Proteomic approaches to biomarker discovery in prostate and bladder cancers. Proteomics 1:1264–1270CrossRefPubMedGoogle Scholar
  2. Adam BL, Qu Y, Davis JW et al. (2002) Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res 62:3609–3614PubMedGoogle Scholar
  3. Ahram M, Best CJ, Flaig MJ et al. (2002) Proteomic analysis of human prostate cancer. Mol Carcinog 33:9–15CrossRefPubMedGoogle Scholar
  4. Ahram M, Flaig MJ, Gillespie JW et al. (2003) Evaluation of ethanol-fixed, paraffin-embedded tissues for proteomic applications. Proteomics 3:413–421CrossRefPubMedGoogle Scholar
  5. Anderson NL, Anderson NG (2002) The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 1:845–867PubMedGoogle Scholar
  6. Bast RC Jr, Klug TL, St John E et al. (1983) A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 309:883–887PubMedCrossRefGoogle Scholar
  7. Blume-Jensen P, Hunter T (2001) Oncogenic kinase signalling. Nature 411:355–365CrossRefPubMedGoogle Scholar
  8. Bobrow MN, Harris TD, Shaughnessy KJ et al. (1989) Catalyzed reporter deposition, a novel method of signal amplification. Application to immunoassays. J Immunol Methods 125:279–285CrossRefPubMedGoogle Scholar
  9. Bobrow MN, Shaughnessy KJ, Litt GJ et al. (1991) Catalyzed reporter deposition, a novel method of signal amplification. II. Application to membrane immunoassays. J Immunol Methods 137:103–112CrossRefPubMedGoogle Scholar
  10. Bowden ET, Barth M, Thomas D et al. (1999) An invasion-related complex of cortactin, paxillin and PKCmu associates with invadopodia at sites of extracellular matrix degradation. Oncogene 18:4440–4449CrossRefPubMedGoogle Scholar
  11. Brown CK, Kirkwood JM (2001) Targeted therapy for malignant melanoma. Curr Oncol Rep 3:344–352PubMedGoogle Scholar
  12. Carlisle AJ, Prabhu VV, Elkahloun A et al. (2000) Development of a prostate cDNA microarray and statistical gene expression analysis package. Mol Carcinog 28:12–22PubMedGoogle Scholar
  13. Carter D, Douglass JF, Cornellison CD et al. (2002) Purification and characterization of the mammaglobin/lipophilin B complex, a promising diagnostic marker for breast cancer. Biochemistry 41:6714–6722CrossRefPubMedGoogle Scholar
  14. Celis JE, Gromov P (2003) Proteomics in translational cancer research: toward an integrated approach. Cancer Cell 3:9–15CrossRefPubMedGoogle Scholar
  15. Charboneau L (2002) Utility of reverse phase protein microarrays: applications to signaling pathways and human body arrays. Brief Funct Genomics Proteomics 1:305–315CrossRefGoogle Scholar
  16. Chaurand P, Caprioli RM (2002) Direct profiling and imaging of peptides and proteins from mammalian cells and tissue sections by mass spectrometry. Electrophoresis 23:3125–3135CrossRefPubMedGoogle Scholar
  17. Cheng JD, Rieger PT, von Mehren M et al. (2000) Recent advances in immunotherapy and monoclonal antibody treatment of cancer. Semin Oncol Nurs 16[4 Suppl 1]:2–12PubMedGoogle Scholar
  18. Cimoli G, Bagnasco L, Pescarolo MP et al. (2001) Signaling proteins as innovative targets for antineoplastic therapy: our experience with the signaling protein c-myc. Tumori 87:S20–S23PubMedGoogle Scholar
  19. Cohen LS, Escobar PF, Sharm C et al. (2001) Three-dimensional power Doppler ultrasound improves the diagnostic accuracy for ovarian cancer prediction. Gynecol Oncol 821:40–48Google Scholar
  20. Conrads TP, Zhou M, Petricoin EF et al. (2003) Cancer diagnosis using proteomic patterns. Expert Rev Mol Diagn 3:411–420CrossRefPubMedGoogle Scholar
  21. Craven RA, Totty N, Harnden P et al. (2002) Laser capture microdissection and two-dimensional polyacrylamide gel electrophoresis: evaluation of tissue preparation and sample limitations. Am J Pathol 160:815–822PubMedGoogle Scholar
  22. Cutler P (2003) Protein arrays: the current state-of-the-art. Proteomics 3:3–18PubMedGoogle Scholar
  23. Emmert-Buck MR, Bonner RF, Smith PD et al. (1996) Laser capture microdissection. Science 274:998–1001CrossRefPubMedGoogle Scholar
  24. Emmert-Buck MR, Gillespie JW, Paweletz CP et al. (2000) An approach to proteomic analysis of human tumors. Mol Carcinog 27:158–165CrossRefPubMedGoogle Scholar
  25. Emmert-Buck MR, Strausberg RL, Krizman DB et al. (2000) Molecular profiling of clinical tissues specimens: feasibility and applications. J Mol Diagn 2:60–66PubMedGoogle Scholar
  26. Espina V, Mehta AI, Winters ME et al. (2003) Protein microarrays: molecular profiling technologies for clinical specimens. Proteomics 3:2091–2100CrossRefPubMedGoogle Scholar
  27. Frankel AE, Sievers EL, Scheinberg DA et al. (2000) Cell surface receptor-targeted therapy of acute myeloid leukemia: a review. Cancer Biother Radiopharm 15:459–476PubMedGoogle Scholar
  28. Gasparini G, Gion M (2000) Molecular-targeted anticancer therapy: challenges related to study design and choice of proper endpoints. Cancer J 6:117–131PubMedGoogle Scholar
  29. Ge H (2000) UPA, a universal protein array system for quantitative detection of protein-protein, protein-DNA, protein-RNA and protein-ligand interactions. Nucleic Acids Res 28:e3CrossRefPubMedGoogle Scholar
  30. Gillespie JW, Best CJ, Bichsel VE et al. (2002) Evaluation of non-formalin tissue fixation for molecular profiling studies. Am J Pathol 160:449–457PubMedGoogle Scholar
  31. Gorg A, Obermaier C, Boguth G et al. (2000) The current state of two-dimensional electrophoresis with immobilized pH gradients. Electrophoresis 21:1037–1053PubMedGoogle Scholar
  32. Graf R, Friedl P (1999) Detection of immobilized proteins on nitrocellulose membranes using a biotinylation-dependent system. Anal Biochem 273:291–297CrossRefPubMedGoogle Scholar
  33. Grubb RL, Calvert VS, Wulkuhle JD et al. (2003) Signal pathway profiling of prostate cancer using reverse phase protein arrays. Proteomics 3:2142–2146CrossRefPubMedGoogle Scholar
  34. Gygi SP, Aebersold R (2000) Mass spectrometry and proteomics. Curr Opin Chem Biol 4:489–494CrossRefPubMedGoogle Scholar
  35. Gygi SP, Rist B, Gerber SA et al. (1999) Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat Biotechnol 17:994–999CrossRefPubMedGoogle Scholar
  36. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57–70CrossRefPubMedGoogle Scholar
  37. Hanash S (2003) Disease proteomics. Nature 422:226–232CrossRefPubMedGoogle Scholar
  38. Hanash SM (2000) Biomedical applications of two-dimensional electrophoresis using immobilized pH gradients: current status. Electrophoresis 21:1202–1209CrossRefPubMedGoogle Scholar
  39. Herrmann PC, Gillespie JW, Charboneau L et al. (2003) Mitochondrial proteome: altered cytochrome c oxidase subunit levels in prostate cancer. Proteomics 3(9):1801–1810CrossRefPubMedGoogle Scholar
  40. Hillenkamp F, Karas M (1990) Mass spectrometry of peptides and proteins by matrix-assisted ultraviolet laser desorption/ionization. Methods Enzymol 193:280–295PubMedGoogle Scholar
  41. Hingorani SR, Petricoin EF, Maitra A et al. (2003) Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 4:437–450CrossRefPubMedGoogle Scholar
  42. Hoskins WJ, Perez CA et al. (eds) (2000) Tumor markers. Lippincott, Williams and Wilkins, PhiladelphiaGoogle Scholar
  43. Hunter T (2000) Signaling-2000 and beyond. Cell 100:113–127CrossRefPubMedGoogle Scholar
  44. Hunyady B, Krempels K, Maitra A et al. (1996) Immunohistochemical signal amplification by catalyzed reporter deposition and its application in double immuno-staining. J Histochem Cytochem 44:1353–1362PubMedGoogle Scholar
  45. Ideker T, Thorsson V, Ranish JA et al. (2001) Integrated genomic and proteomic analyses of a systematically perturbed metabolic network. Science 292:929–934CrossRefPubMedGoogle Scholar
  46. Jacobs IJ, Skates SJ, MacDonald N et al. (1999) Screening for ovarian cancer: a pilot randomised controlled trial. Lancet 353:1207–1210CrossRefPubMedGoogle Scholar
  47. Jeong H, Tombor B, Albert R et al. (2000) The large-scale organization of metabolic networks. Nature 407:651–654PubMedGoogle Scholar
  48. Jones MB, Krutzsch H, Shu H et al. (2002) Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer. Proteomics 2:76–84CrossRefPubMedGoogle Scholar
  49. Karpati G, Li H, Nalbantoglu J et al. (1999) Molecular therapy for glioblastoma. Curr Opin Mol Ther 1:545–552PubMedGoogle Scholar
  50. Kim JH, Skates SJ, Uede T et al. (2002) Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 287(13):1671–1679CrossRefPubMedGoogle Scholar
  51. King G, Payne S, Walker F et al. (1997) A highly sensitive detection method for immunohistochemistry using biotinylated tyramine. J Pathol 183(2):237–41CrossRefPubMedGoogle Scholar
  52. Knezevic V, Leethanakul C, Bichsel VE et al. (2001) Proteomic profiling of the cancer microenvironment by antibody arrays. Proteomics 1:1271–1278CrossRefPubMedGoogle Scholar
  53. Kolonin M, Pasqualini R, Arap W et al. (2001) Molecular addresses in blood vessels as targets for therapy. Curr Opin Chem Biol 5:308–313CrossRefPubMedGoogle Scholar
  54. Kukar T, Eckenrode S, Gu Y et al. (2002) Protein microarrays to detect protein-protein interactions using red and green fluorescent proteins. Anal Biochem 306:50–54CrossRefPubMedGoogle Scholar
  55. Lai SP, Christopherson RI, dos Remedios CG et al. (2002) Antibody arrays: an embryonic but rapidly growing technology. Drug Discov Today 7[18 Suppl]:S143–S149Google Scholar
  56. Leak LV, Petricoin EF 3rd, Jones M et al. (2002) Proteomic technologies to study diseases of the lymphatic vascular system. Ann N Y Acad Sci 979:211–228; discussion 229–234PubMedCrossRefGoogle Scholar
  57. Legrain P, Jestin JL, Schachter V et al. (2000) From the analysis of protein complexes to proteome-wide linkage maps. Curr Opin Biotechnol 11:402–407CrossRefPubMedGoogle Scholar
  58. Li J, Zhang Z, Rosenzweig J et al. (2002) Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 48:1296–1304PubMedGoogle Scholar
  59. Liotta L, Petricoin E (2000) Molecular profiling of human cancer. Nat Rev Genet 1:48–56CrossRefPubMedGoogle Scholar
  60. Liotta LA, Kohn EC (2001) The microenvironment of the tumour-host interface. Nature 411:375–379CrossRefPubMedGoogle Scholar
  61. Liotta LA, Kohn EC, Petricoin EF et al. (2001) Clinical proteomics: personalized molecular medicine. JAMA 286:2211–2214CrossRefPubMedGoogle Scholar
  62. Liotta LA, Espina V, Mehta AI et al. (2003) Protein microarrays: Meeting analytical challenges for clinical applications. Cancer Cell 3:317–325CrossRefPubMedGoogle Scholar
  63. Liotta LA, Ferrari M, Petricoin E et al. (2003) Clinical proteomics: written in blood. Nature 425:905CrossRefPubMedGoogle Scholar
  64. MacBeath G (2002) Protein microarrays and proteomics. Nat Genet 32[Suppl]:526–532PubMedGoogle Scholar
  65. MacBeath G, Schreiber SL (2000) Printing proteins as microarrays for high-throughput function determination. Science 289:1760–1763PubMedGoogle Scholar
  66. MacDonald TJ, Brown KM, Petricoin E et al. (2001) Expression profiling of medullo-blastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease. Nat Genet 29:143–152CrossRefPubMedGoogle Scholar
  67. Mehta AI, Ross S, Lowenthal M et al. (2003) Biomarker amplification by serum carrier protein binding. Disease Markers 19:1–10PubMedGoogle Scholar
  68. Menon U, Jacobs IJ (2000) Recent developments in ovarian cancer screening. Curr Opin Obstet Gynecol 12:39–42CrossRefPubMedGoogle Scholar
  69. Morozov VN, Gavryushkin AV, Deev AA et al. (2002) Direct detection of isotopically labeled metabolites bound to a protein microarray using a charge-coupled device. J Biochem Biophys Methods 51:57–67CrossRefPubMedGoogle Scholar
  70. Ornstein DK, Gillespie JW, Paweletz CP et al. (2000) Proteomic analysis of laser capture microdissected human prostate cancer and in vitro prostate cell lines. Electrophoresis 21:2235–2242CrossRefPubMedGoogle Scholar
  71. Paweletz CP, Gillespie JW, Ornstein DK et al. (2000) Rapid protein display profiling of cancer progression directly from human tissue using a protein biochip. Drug Dev Res 49:34–42CrossRefGoogle Scholar
  72. Paweletz CP, Charboneau L, Bichsel VE et al. (2001) Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene 20:1981–1989CrossRefPubMedGoogle Scholar
  73. Pawson T (1995) Protein modules and signalling networks. Nature 373:573–580PubMedGoogle Scholar
  74. Petricoin EF, Liotta LA (2003) Mass spectrometry-based diagnostics: the upcoming revolution in disease detection. Clin Chem 49:533–534PubMedGoogle Scholar
  75. Petricoin EF 3rd, Ornstein DK, Paweletz CP et al. (2002) Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst 94:1576–1578PubMedGoogle Scholar
  76. Petricoin EF, Ardekani AM, Hitt BA et al. (2002) Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359:572–577PubMedCrossRefGoogle Scholar
  77. Petricoin EF, Zoon KC, Kohn EC et al. (2002) Clinical proteomics: translating benchside promise into bedside reality. Nat Rev Drug Discov 1:683–695CrossRefPubMedGoogle Scholar
  78. Rosty C, Christa L, Kuzdzal S et al. (2002) Identification of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology. Cancer Res 62:1868–1875PubMedGoogle Scholar
  79. Schwartz SA, Weil RJ, Johnson MD et al. (2004) Protein profiling in brain tumors using mass spectrometry: feasibility of a new technique for the analysis of protein expression. Clin Cancer Res 10:981–987PubMedGoogle Scholar
  80. Schweitzer B, Roberts S, Grimwade B et al. (2002) Multiplexed protein profiling on microarrays by rolling-circle amplification. Nat Biotechnol 20:359–365CrossRefPubMedGoogle Scholar
  81. Schwikowski B, Uetz P, Fields S et al. (2000) A network of protein-protein interactions in yeast. Nat Biotechnol 18:1257–1261CrossRefPubMedGoogle Scholar
  82. Shen Y, Tolic N, Zhao R et al. (2001) High-throughput proteomics using high-efficiency multiple-capillary liquid chromatography with on-line high-performance ESI FTICR mass spectrometry. Anal Chem 73:3011–3021PubMedGoogle Scholar
  83. Shen Y, Tolic N, Masselon C et al. (2004) Ultrasensitive proteomics using high-efficiency on-line micro-SPE-nanoLC-nanoESI MS and MS/MS. Anal Chem 76:144–154PubMedGoogle Scholar
  84. Simone NL, Remaley AT, Charboneau L et al. (2000) Sensitive immunoassay of tissue cell proteins procured by laser capture microdissection. Am J Pathol 156:445–452PubMedGoogle Scholar
  85. Stillman BA, Tonkinson JL (2000) FAST slides: a novel surface for microarrays. Biotechniques 29:630–635PubMedGoogle Scholar
  86. Stoeckli M, Chaurand P, Hallahan DE et al. (2001) Imaging mass spectrometry: a new technology for the analysis of protein expression in mammalian tissues. Nat Med 7:493–496CrossRefPubMedGoogle Scholar
  87. Templin MF, Stoll D, Schrenk M et al. (2002) Protein microarray technology. Trends Biotechnol 20:160–166CrossRefPubMedGoogle Scholar
  88. Tirumalai RS, Chan KC, Prieto DA et al. (2003) Characterization of the low molecular weight human serum proteome. Mol Cell Proteomics 2:1096–1103PubMedGoogle Scholar
  89. Tonkinson JL, Stillman BA (2002) Nitrocellulose: a tried and true polymer finds utility as a post-genomic substrate. Front Biosci 7:c1–12PubMedGoogle Scholar
  90. Tyers M, Mann M (2003) From genomics to proteomics. Nature 422:193–197CrossRefPubMedGoogle Scholar
  91. Warburg O, Posenor K, Negellein E et al. (1924). Biochem Z 152:309–345Google Scholar
  92. Wiese R (2003) Analysis of several fluorescent detector molecules for protein microarray use. Luminescence 18:25–30CrossRefPubMedGoogle Scholar
  93. Wilson DS, Nock S (2003) Recent developments in protein microarray technology. Angew Chem Int Ed Engl 42:494–500PubMedGoogle Scholar
  94. Wulfkuhle JD, McLean KC, Paweletz CP et al. (2001) New approaches to proteomic analysis of breast cancer. Proteomics 1:1205–1215CrossRefPubMedGoogle Scholar
  95. Wulfkuhle JD, Sgroi DC, Krutzsch H et al. (2002) Proteomics of human breast ductal carcinoma in situ. Cancer Res 62:6740–6749PubMedGoogle Scholar
  96. Wulfkuhle JD, Aquino JA, Calvert VS et al. (2003) Signal pathway profiling of ovarian cancer from human tissue specimens using reverse-phase protein microarrays. Proteomics 3:2085–2090CrossRefPubMedGoogle Scholar
  97. Wulfkuhle JD, Liotta LA, Petricoin EF (2003) Proteomic applications for the early detection of cancer. Nat Rev Cancer 3:267–275CrossRefPubMedGoogle Scholar
  98. Xiao Z, Adam BL, Cazares LH et al. (2001) Quantitation of serum prostate-specific membrane antigen by a novel protein biochip immunoassay discriminates benign from malignant prostate disease. Cancer Res 61:6029–6033PubMedGoogle Scholar
  99. Yanagisawa K, Shyr Y, Xu BJ et al. (2003) Proteomic patterns of tumour subsets in non-small-cell lung cancer. Lancet 362:433–439CrossRefPubMedGoogle Scholar
  100. Zhu H, Snyder M (2001) Protein arrays and microarrays. Curr Opin Chem Biol 5:40–45CrossRefPubMedGoogle Scholar
  101. Zhu H, Snyder M (2003) Protein chip technology. Curr Opin Chem Biol 7:55–63CrossRefPubMedGoogle Scholar

Copyright information

© Springer Berlin Heidelberg 2005

Authors and Affiliations

  • David H. Geho
  • Lance A. Liotta
  • Emanuel F. Petricoin

There are no affiliations available

Personalised recommendations